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Abstract
Background: A subset of lung adenocarcinoma with EGFR-tyrosine kinase inhibitor sensitizing mutations (mEGFR)
is common in non-smokers and women, suggesting that mutational stressors other than smoking are involved.
Methods: Targeted sequencing using a custom panel containing 70 cancer-related genes were performed from 73
cases of lung adenocarcinoma with mEGFR (study cohort). In parallel, publicly available data of 47 TCGA-LUAD
cases with mEGFR (LUAD cohort) were extracted from the GDC data portal and analyzed by non-negative matrix
factorization using the Maftools package.
Results: In the study cohort, the C > A transversions accounted for 12.9% of all single nucleotide variations (SNVs),
comprising the second smallest proportion among SNVs. The E19del-subgroup had a significantly lower mutational
burden with significantly higher Ti/Tv ratio than the SNV-subgroup, which includes cases with L858R and other EGFR-
TKI sensitizing SNVs. (P = 0.0326 and 0.0002, respectively, Mann-Whitney U test). In the LUAD cohort, the mutational
burden was substantially lower than in other TCGA cancer cohorts, and the frequency of C > A transversions was 30.
3%, occupying the second frequency. The E19del-subgroup had a lower mutational burden overall and a higher Ti/Tv
ratio than the SNV-subgroup (P = 0.0497 and P = 0.0055, respectively, Mann-Whitney U test). Smoking-related signature
4 was observed only in the L858R-subgroup, while ignature 30 and 5 was observed in both groups.
Conclusions: Lung adenocarcinoma with mEGFR(+) has a lower mutational burden and does not show a
characteristic mutation pattern influenced by smoking. E19del and L858R, which are representative subtypes of
mEGFR(+) lung adenocarcinoma, differ in terms of mutational spectrum, as the E19del-subgroup has a lower mutation
burden and a higher Ti/Tv ratio than the SNV-subgroup. These findings could help explain the differences in the
responses to EGFR-TKIs and in the clinical courses between the two lung adenocarcinoma subgroups.
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Background
According to the 2015 annual report, 1,824,700 new
lung cancer cases are diagnosed each year, which ac-
counts for 13% of all cancers, excluding non-melanoma
skin cancers. In addition, it is still the leading cause of
cancer mortality worldwide, suggesting that lung cancer
is a major problem for healthcare worldwide [1]. Ac-
cording to the 2015 yearbook of the National Cancer
Registration and Statistics in Korea, lung cancer oc-
curred in 66.0 per 100,000 males and 28.7 per 100,000
females [2]. Compared to other countries, Korea is 10th
in the incidence of male lung cancer and 4th in the inci-
dence of female lung cancer [3]. The total incidences in
Korea are not significantly different from other coun-
tries, but the incidence of lung cancer is higher in
non-smokers and women in Korea, and epidermal
growth factor receptor (EGFR) mutations are detected
much more frequently than in Western countries.
The main causes of lung cancer are direct and indir-
ect smoking, radon, indoor emissions from household
combustion, and exhaust from diesel engines (https://
monographs.iarc.fr/agents-classified-by-the-iarc/) [4].
Mutational analysis of lung cancer using publicly available
data such as TCGA has shown that the smoke-related sig-
nature, with many C >A transversions, is a dominant sig-
nature in lung adenocarcinoma and lung squamous cell
carcinoma [5]. Somatic mutations in cancer are caused in-
fidelity of the DNA replication machinery as well as and
defects in DNA repair mechanisms following exposure to
endogenous or exogenous mutagens [6]. The somatic mu-
tations observed in some cancers are significantly related
to exposure to a specific carcinogen, such as smoking in
lung cancer and ultraviolet light in skin cancer [7].
Certain mutational processes in cancer often accompany
unique combinations of mutation types called signatures
[8, 9]. Recently, Alexandrov et al. developed a theoretical
model and computational framework that could decon-
struct unique patterns of somatic mutations using cancer
specimen sequencing data based on the analysis of som-
atic substitutions obtained from whole genome sequen-
cing of breast cancer patients [10, 11]. Among the 30
signatures, signature 4, which is characterized by a major-
ity of C > A mutations along with some other base substi-
tution classes, is found only in cancer types in which
smoking is a major risk factor and in epithelial cancers
that are directly exposed to cigarette smoke. The muta-
tional signature is similar to the mutational pattern result-
ing from exposing cells to benzo [a] pyrene, a major
carcinogen in tobacco. This mutational pattern occurs in
the process of nucleotide excisional repair after binding of
a bulky DNA adduct to the guanine [5, 8].
Given that lung adenocarcinoma with EGFR-tyrosine kin-
ase inhibitor (TKI) sensitizing mutation (mEGFR) is com-
mon in light and/or non-smokers, Asians, and women, it is
expected to have mutational pressures other than cigarette
smoking, [12]. The L858R mutation and the exon 19 dele-
tion (E19del), which includes the LREA motif, comprise up
to 90% of EGFR mutations, followed by L861Q, G719X,
and rare mutations [13]. The clinical outcomes of mEGFR
positive lung cancers have dramatically improved due to
the development of target drugs, but these cancers eventu-
ally acquire drug resistance and show disease progression
[14, 15]. The clinical courses and responses to EGFR-TKIs
differ between the E19del and L858R groups, which are
representative subtypes of mEGFR [16]. Therefore, the
identification of carcinogenesis by the estimation of signifi-
cant mutagenic stressors is needed, along with a proactive
approach for these subtypes of cancer.
Therefore, we investigated whether there is a distinct-
ive mutation pattern in the subtypes of lung adenocar-
cinoma responsive to EGFR-TKI. Targeted sequencing
was performed on major cancer-related genes using lung
adenocarcinoma with mEGFR (study cohort), and the
characteristics of the obtained mutations were analyzed.
In addition, the mutation characteristics of the L858R
and E19del subtypes, which occupy the majority of the
mEGFR, were compared and analyzed. Finally, whole ex-
ome sequencing data from TCGA-LUAD with mEGFR
(LUAD cohort), which are publicly available, were ana-
lyzed and used to verify the mutational characteristics of
study cohort. The characteristics of the genetic varia-
tions were analyzed in the context of the mutational sig-
nature proposed by Alexandrov et al. [17].
Methods
Study cases
A total of 74 lung adenocarcinoma tissues which met
the following criteria were randomly selected from the
tissue archives of two affiliated hospitals, Severance Hos-
pital and Gangnam Severance Hospital, of Yonsei Med-
ical Center (study cohort). Each specimen (1) is a
pathologically confirmed lung adenocarcinoma, (2) had
history of curative surgical resection, (3) has a submis-
sion of informed consent for sequencing of major cancer
related genes, (4) was confirmed to have mEGFR either
by Sanger sequencing or PNA clamping methods, and
(5) has submission of informed consent for tissue collec-
tion. This study was approved by the IRB of Gangnam
Severance Hospital (IRB #3–2017-0059) and was carried
out in compliance with the Declaration of Helsinki
(https://www.wma.net/policies-post/wma-declaration-of-
helsinki-ethical-principles-for-medical-research-involving-hu-
man-subjects/) and Korean GCP guidelines. In order to
further evaluate the mutational characteristics of lung
adenocarcinoma with mEGFR, publicly available data were
extracted from the GDC Data Portal of The Cancer Gen-
ome Atlas (TCGA https://portal.gdc.cancer.gov/). Among
the 585 TCGA-LUAD cases, 81 cases harbor mutations in
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the EGFR gene (ENSG00000146648) with 47 types listed
in TCGA-LUAD (Additional file 1: Table S1). A total of
7577 mutations were found in 48 TCGA-LUAD cases;
TCGA-55-8506 has 2305 mutations alone, accounting for
30.4% of all mutations, and was excluded from further
analysis. For this analysis, we selected 47 cases with 7
EGFR subtypes known as common mEGFR (LUAD co-
hort) (Additional file 2: Table S2 and Additional file 3:
Table S3) (8).
Next generation sequencing: A 0.62Mb customized
NGS panel containing 70 major cancer genes was con-
structed and sequenced using the Ion S5 NGS system
(Thermo Fisher Scientific) (Additional file 4: Table S4).
For the extraction of cancer-enriched gDNA, paraffin-em-
bedded tissue samples were loaded onto silanated slides in
4-μm-thickness sections. Each slide was lightly stained with
H&E and examined for the presence of cancer cells. The
cancer-enriched area as determined by an independent lung
pathologist was marked and scraped with clean blades.
gDNA was extracted using a QIAamp DNA FFPE Tissue Kit
(Qiagen, Valencia, CA, USA). Fifty ng of extracted DNA was
reacted with fragmentizer for 12 to 50min (Archer) and the
section of cut DNA was blunted and 5′ phosphorylated with
an end-repair enzyme (Archer). The end of the DNA was
barcode-ligated through a reaction with an MBC adapter
(Archer) for 15min, and 1st and 2nd PCR were performed
using a primer set for the selected target genes. After meas-
uring the prepared library with Qubit , 50 pmol of sample
was obtained and mixed with mineral oil to normalize it with
beads. The sample was applied to a 540 Chip (Life Technol-
ogy) and sequenced with the S5 sequencer (Life technology).
The obtained results were analyzed by Archer Analysis 5.1
(Archer) and the median depth of the sequencing was 308X
[164.5 ~ 738.5].
Statistics
Categorical and continuous variables were compared using
χ2-tests and t-test, respectively. Differences in the distribu-
tion of continuous variables between the two independent
samples and dependent samples were assessed by Mann–
Whitney U test and Wilcoxon signed-rank test, respect-
ively. The Kruskal-Wallis test was used to compare the me-
dians of three or more groups, and the Bonferroni method
was used for the post-hoc test. The mutational signature
was analyzed using R software and the Maftools package
[18]. Briefly, the pattern of the mutation is analyzed under
the 3-nucleotide context, which includes one nucleotide
immediately 5′ and 3′ of the mutated base [10, 17] to
characterize single base substitution using a 96-mutation
classification by combining 6 substitution types and the 5′
and 3′ adjacent bases to the mutated base. The mutation
patterns found in cancers are analyzed by non-negative
matrix factorization (NMF), and compared to 30 types of
mutational signatures [8]. All analyses were performed
using SPSS version 23 (SPSS Inc., Chicago, IL, USA). All
statistical tests were two-sided, and a P-value < 0.05 was
considered to be statistically significant.
Results
Characteristics of study cohort
The incidence of lung adenocarcinoma harboring
EGFR-TKI-sensitizing mutations is higher in East Asia
than in Western countries, and the proportion of
non-smokers and women is high, suggesting the pres-
ence of mutagenic stressors other than cigarette smok-
ing. We conducted targeted sequencing of 70 major
cancer-related genes on a total 73 specimens recruited
from 71 patients, including two cases with double pri-
mary cancer (Table 1 and Additional file 5: Table S5).
These included 37 cases with EGFR exon19 deletion
mutation, 35 cases with L858R mutation and one case
with the L861Q mutation. The mean age of the patients
was 60.34 ± 10.01 years, and they were comprised of 25
males and 46 females. Of these, 20 cases had a history of
smoking, with a mean of 22.75 ± 13.33 pack-years.
C > A transversion accounts for small fraction in study
cohort
The sequencing of 73 specimens revealed 530 mutations
consisting of 490 single and double nucleotide substitu-
tions, 1 insertion, and 39 deletions. The median of total
mutations obtained from each sample was 6 [5 ~ 8]
(Fig. 1A and B). These mutations were further classified
according to the variant effect predictor (VEP) and the
results are shown in Fig. 1C and Table 2. C > A transver-
sion, which is attributed to cigarette smoking, is the
most common type of SNV in lung cancer [5]; therefore,
we questioned whether this finding also applies to Ko-
rean lung adenocarcinomas with mEGFR. Excluding the
mutations which were assumed to be benign because
they did not change protein behaviors by the VEP, and
indels and doublets, a total of 363 SNVs were classified
and analyzed (Fig. 1D and E). In this subset, C > T tran-
sition accounted for the largest portion (27.3%), followed
by C > G transition (20.4%), whereas C > A transversion
occupied the second smallest fraction (12.9%). The fre-
quency of C > A transversion was statistically signifi-
cantly lower than those of other mutations, except for
T > A and T > G transversions, which differs from the
general notion that NSCLC harbors higher C > A trans-
versions due to cigarette smoking. The differences in the
frequencies of Ti and Tv did not reach statistically sig-
nificant level in each individual case (Fig. 1F).
Lung adenocarcinoma with the E19del mutation has a
significantly lower mutational burden, higher Ti/Tv ratio
To identify the presence of smoking effects, we exam-
ined whether there was a difference in the mutational
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spectrum between cases with vs. without a smoking his-
tory. There was no statistically significant difference in
the total number of mutations between smoker and
non-smoker groups and between those with more than a
20-pack-year history and the other cases. There was no
significant difference in the frequencies of Ti, Tv, and
Ti/Tv ratio according to the smoking history. These
findings were similar to the comparison of mutation pat-
terns according to gender, which showed no differences
in the total mutational burden, frequencies of Ti and Tv,
and Ti/Tv ratios between genders. Then, we questioned
whether the subtypes of mEGFR are related to the differ-
ence in mutation burden, Ti, Tv, and Ti/Tv ratio. In
order to accomplish this, the cases were classified into
either the mEGFR E19del-subgroup or the mEGFR
SNV-subgroup, which includes cases with L858R,
L861Q, and other EGFR-TKI sensitizing SNVs. In the
E19del-subgroup, there was no statistically significant
difference in the frequency of Ti and Tv in each individ-
ual, whereas the frequency of Tv was significantly higher
than Ti in the mEGFR SNV-subgroup (P = 0.0020, Wil-
coxon signed rank test). There was a significant differ-
ence in the total number of mutations, as the
E19del-subgroup had a lower mutational burden than
the SNV-subgroup (P = 0.0326, Mann-Whitney U test).
The E19del-subgroup had lower Tv and a higher Ti and
Ti/Tv ratio than the SNV-subgroup (P = 0.0441, =0.0020,
and = 0.0002, respectively, Mann-Whitney U test,
Fig. 2A~D). As C > A transversion was less frequent than
in general lung cancer, this suggests that some muta-
genic stress other than cigarette smoking likely exists in
this subset of lung adenocarcinomas. To identify the
mutagenic stressors that influence mEGFR-positive lung
adenocarcinomas, we analyzed the mutational signature
proposed by Alexandrov et al. (4). When the three
best-matched mutational signatures were estimated
using non-negative matrix factoralization (NMF), signa-
ture 5 and signature 3 was derived (Fig. 2E and F).
Among smoking history, gender, and EGFR-mutation
subtype, only EGFR subtype showed a difference in the
distributions of Ti and Tv. We further analyzed the mu-
tational signatures between the E19del-subgroup and the
SNV-subgroup using NMF. In the subgroup analysis on
the mutational, signature 5 is the predominant muta-
tional signature in this study cohort (Data not shown).
LUAD cohort has a lower mutational burden than other
TCGA cancer cohorts
The mean age of the 47 selected cases was 66.20 ± 9.44
years, and the cases were comprised of 11 males, 34
Table 1 Demographic characteristics of the 2 cohorts according to the EGFR-TKI mutation subtypes
SNV* E19del** P-value
Study cohort (n = 71)† Age 62.58 ± 9.67 58.03 ± 9.95 0.0547‡‡
Gender Male 14 11 0.6822§
Female 22 24
Smoking history Ever smoker 11 9 0.8497§
None smoker 25 26




LUAD cohort (n = 47) §§ Age 66.56 ± 9.18 65.81 ± 10.40 0.8138‡‡
Gender Male 7 4 0.9234§
Female 10 14
Smoking history Ever smoker 15 4 0.0540§
None smoker 13 15




* Study cohort of SNV subgroup includes one L861Q variant and LUAD cohort of SNV subgroup includes 3 cases of L861Q, 2 G719A, and 1 G719C variant
**Includes E19 inframe del variants including LREA motif
† Includes 2 cases with double primary tumor
‡‡ P-values were obtained by independent sample t-test
§ P-values were obtained by chi-square test
§§The clinical information of 2 cases is not available
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females, and two cases in which the gender was not re-
ported (Table 1). Of these, 19 had a smoking history. A
total of 5272 mutations were recovered from 47
EGFR-TKI-sensitive mutation-positive TCGA-LUAD
cases. The median number of total mutations obtained
from each sample was 78 [56 ~ 112.5], which indicates
that the mutational burden was significantly lower than
that of other cancer types listed in the TCGA dataset
and the TCGA-LUAD parent group (Fig. 3A and B).
These 5272 mutations are classified into 4954 single nu-
cleotide substitutions, 146 insertions, and 172 deletions
(Fig. 3C). These mutations were further classified ac-
cording to the VEP and the results are shown in the
Table 3 and Fig. 3D.
C > T transition is the most common type of SNV
Because C > A transversion, which is attributed to
cigarette smoking, is the most common variation in
Fig. 1 Characteristics of the variations in the study cohort. Histogram showing the cumulative frequency of variation for individual cases (a).
Stacked bar chart summarizing the variant types of all cases with substitutions, insertions, and deletions (b). Bundled bar chart classifying
variations using the VEP (c). Bundled column chart showing the SNV classification of individual cases (d). Box plot summarizing the SNV of study
cohort (e). Box plot created by dividing the SNV into Ti and Tv (f). n.s* not significant
Table 2 Classification of variants in study cohort according to
the VEP







Inframe insertion and deletion 37
Nonstop mutation 0
Total 530
Kim et al. BMC Cancer         (2018) 18:1221 Page 5 of 10
NSCLC [5], we questioned whether this finding also ap-
plies to this subset of NSCLC. 1179 mutations, including
1071 synonymous mutations, 47 mutations in the splice
region, and 1 stop retaining mutation, were assumed to
be harmless or unlikely to change protein behaviors by
the VEP; these SNVs along with insertions and deletions
were excluded, and 3812 SNVs were classified and ana-
lyzed (Fig. 3E and F). In this subset, C > T transition
accounted for the largest portion (32.7%), followed by
C > A transversion (30.3%). There was no significant dif-
ference in the frequency of C > T vs. C > A mutations in
each individual, which contradicts the general notion
that NSCLCs harbor higher C > A transversions than
any other SNV. The difference in the frequencies of Ti
and Tv in each individual case was not statistically sig-
nificant (Fig. 3G).
Different mutational spectra between the E19del and
SNV-subgroups
The differences in the mutational pattern observed in
the study cohort were further verified in the LUAD co-
hort. The mutational burden did not differ between the
groups with and without a smoking history. In addition,
there were no differences in the Ti, Tv, and Ti/Tv ratio
according to smoking history or between smokers and
non-smokers. There was also no significant difference in
the total mutational burden or the frequency of Ti, Tv,
and Ti/Tv ratio between genders. Finally, we questioned
whether the subtypes of EGFR-TKI-sensitizing muta-
tions were related to the difference in mutational bur-
den, Ti, Tv, and Ti/Tv ratio. As seen in the study cohort,
there was no statistically significant difference in the fre-
quency of Ti and Tv in each individual in the
E19del-subgroup, whereas the frequency of Tv was sig-
nificantly higher than Ti in the mEGFR SNV-subgroup
(P = 0.0220, Wilcoxon signed rank test). In the
E19del-subgroup, the total mutation burden and the
number of Tv mutations were significantly lower than in
the SNV-subgroup (p = 0.0497 and = 0.0220, respectively,
Mann-Whitney U test) and the Ti/Tv ratio was signifi-
cantly higher as well (P = 0.0055, Mann-Whitney U test)
(Fig. 4A and B).
Heterogeneity of mutational signatures between TCGA-
LUAD cases with EGFR-TKI-sensitizing mutations
Next, in order to estimate the mutagenic stress that in-
fluenced EGFR mutations, we analyzed the LUAD co-
hort using the mutational signature proposed by
Alexandrov et al. (4). When inferring the mutagenic
stress using NMF, signature 4 (cosine similarity = 0.851),
signature 30 (cosine similarity = 0.775), and signature 5
(cosine similarity = 0.713) were derived (Fig. 4C and D).
Because the subset analysis of LUAD cohort according
to smoking history, gender, and EGFR mutation subtype
showed that only the subtype influenced the distribution
of mutational burden, Ti, and Tv, we compared the
Fig. 2 Mutational pattern of study cohort. Box plot summarizing the SNV and box plot of Ti and Tv in the E19del-subgroup (a and b) and in the
SNV-subgroup (c and d). Mutational signature plot derived from a 74 X 96 matrix analyzed using the NMF, where 74 is the number of the study
cohort (e) and bar graph indicating the degree to which each case contributed to the signature (f). *n.s. not significant. ** P-value was obtained
by Wilcoxon signed rank test
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mutational signatures between the E19del-subgroup and the
SNV-subgroup. In the E19del-subgroup, signature 30 (co-
sine similarity = 0.741, unknown etiology) and signature 5
(cosine similarity = 0.725 and = 0.660, unknown etiology)
were derived, whereas signature 4 (cosine similarity = 0.842,
smoking effect), signature 30 (cosine similarity = 0.789, un-
known etiology) and signature 5 (cosine similarity = 0.738
unknown etiology) were obtained from the SNV-subgroup
(Fig. 4E and F). Taken together, the mutational signatures
differ between the E19del-subgroup and the SNV-subgroup,
as smoking related signature 4 was observed only in
SNV-subgroup, and signature 5 and 30 are the prevalent
underlying mutational signature in lung adenocarcinoma
with mEGFR-TKI.
Discussion
mEGFR-positive lung adenocarcinoma is a distinctive
subtype of lung cancer which attracts attention because
Fig. 3 Characterization of mutations in LUAD cohort. Histogram showing the cumulative frequency of variation for individual cases (a). Scatter
plot comparing the mutational loads of LUAD cohort with other TCGA cancer cohorts (b). Stacked bar chart summarizing the variant types of all
cases with substitutions, insertions, and deletions (c). Bundled bar chart classifying variations using the VEP (d). Bundled column chart showing
the SNV classification of individual cases (e). Box plot summarizing the SNV of all cases (f) Box. Plot created by dividing the SNV into Ti and Tv (g).
*n.s. not significant
Table 3 Classification of variants in LUAD cohort according to
the VEP







Inframe insertion and deletion 48
Nonstop mutation 2
Total 5272
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it is a prevalent disease which accounts for about half of
East Asian lung adenocarcinomas and because of the
facts that it does not involve the typical risk factors for
lung cancer such as age, gender, and smoking [19].
The proportion of C > A transversions, which is related
to tobacco smoking, was not the major SNV, whereas
C > T transitions comprise the highest proportions of
mutations in both cohorts. Another interesting finding is
that the proportion of C > A transversions is relatively
high in the LUAD cohort than study cohort, which may
be explained by the fact that the cases in the LUAD co-
hort had a higher smoking history than that of the study
cohort (LAUD cohort: 40.4% vs. study cohort: 27.8%).
Further analysis of LUAD cohort according to EGFR
subtype revealed that the Tv frequency was relatively
higher, and mutation signature 4 was observed in the
SNV-subgroup. Although signature 4 was not derived in
the study cohort, it is presumed that mutagenic stressors
such as smoking are related to the L858R mutation be-
cause the Tv frequency is higher, similar to the LUAD
cohort. The E19del-subgroup had lower mutational bur-
den than the SNV subgroup. Both the data from the tar-
geted panel of this study and whole exome data from
TCGA-LUAD showed that the mutations of E19del sub-
group randomly distributed throughout the genome and
the obvious causes could not be detected in the demo-
graphic characteristics of E19del subgroup. Younger age
in the study cohort and less smoking history in LUAD
cohort subgroup might be attributed to these findings.
Mutational signature 5 was main variation pattern in the
study cohort, whereas signatures 4, 30, and 5 were
derived from the analysis of the LUAD cohort. These
differences may be attributed to factors such as the
higher proportion of smokers in the EGFR-L858R group
and higher age in the LUAD cohort compared to the
study cohort (LUAD cohort: 66.30 ± 9.54 vs. study
Fig. 4 Mutational signatures of LUAD cohort. Box plot summarizing the SNV and box plot of Ti and Tv in the LUAD E19del-subgroup (a) and in
the LUAD SNV-subgroup (b). Mutational signature plot derived from a 47 X 96 matrix analyzed using the NMF, which had 37 mEGFR -positive
TCGA-LUAD cases (c) and bar graph indicating the degree to which each case contributed to the individual mutational signature (d). Mutational
signatures obtained from the E19del- subgroup (e) and LUAD SNV-subgroup (f). *n.s. not significant. ** P-value was obtained by Wilcoxon signed
rank test
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cohort: 60.51 ± 10.31 years), and unidentified racial dif-
ferences. However, during additional analysis by sub-
groups, signature 5 was predominant and commonly
derived, indicating that this maybe one of the key muta-
tional signatures in this cancer type.
The underlying mutational mechanism for signature 5,
which exhibits a transcriptional strand bias for T > C
substitutions at ApTpN context, is yet to be well eluci-
dated. This signature is common in papillary cell renal
carcinoma, neuroblastoma, and clear cell renal carcin-
oma and, in some cancer types, is associated with in-
creased age. However, the correlation between signature
5 and increased age was not observed in the analysis of
whole exome sequencing of lung cancer, and it was ob-
served even when we examined the demographic charac-
teristics of our lung cancer set [20]. Among the cancers
arising in the kidney, this mutation is characteristic of
clear cell and papillary renal cell carcinoma, which absorbs
metabolites continuously, whereas it is low in chromo-
phobe renal carcinoma in cortical collecting ducts, sug-
gesting that it may be attributable to the replication error
of deaminated cytosine and adenine [21]. Indeed, relent-
less efforts are required to find out mutagenic stressors
other than smoking, such as radon, indoor emissions from
household combustion, and exhaust from diesel engines,
by collecting the cases enriched with signature 5 and in-
vestigating them in various aspects. In contrast, the muta-
tional signature 30, found in a small subset of breast
cancers, was observed in the analysis of LUAD cohort; the
cause of this mutation pattern has yet to be estimated.
To find out recurrent mutations in specific genes ac-
cording to the mEGFR subtypes, concurrent mutation was
detected by oncoplot and then detected mutations were
further examined using the oncodrive function in maftools
package, which based on algorithm oncodriveCLUST [22].
In this inspection, the E19del subgroup of study cohort
had concurrent mutations in the following order; TP53 >
IDH2 > FBXW7 and in the SNV subgroup; TP53 >
FBXW7 > KRAS. On the other hands, E19del subgroup of
LUAD cohort has concurrent mutations as following
order; CDKN2A >CEP76 > KIAA2026 and SNV subgroup;
AP3D1 > EMR1 > FASTKD3. The mutations observed
here were randomly distributed on the genes, and other
recurrent driver mutations except mEGFR were not
derived.
Targeted sequencing using the Foundation One panel
could reflect the results of whole exome sequencing, in
terms of the mutational burden [23]. This study was car-
ried out based on this assumption, however, the analysis
of study cohort using a customized panel containing 70
major genes covering 0.62Mb is concerning in terms of
direct comparison with the LUAD cohort, which is
based on whole exome sequencing. In the future, if the
cost is further reduced, it may be necessary to find a
minimum sequencing area that can represent whole ex-
ome sequencing.
Taken together, the subtype of lung adenocarcinoma
with EGFR-TKI-sensitizing mutations does not show a
characteristic mutation pattern influenced by smoking
and additionally shows a low incidence of C > A trans-
version, which is a common feature of lung cancer; it
also had a mutational burden lower than those of other
TCGA cancers. E19del and L858R, which are represen-
tative subtypes of lung adenocarcinoma, differ in the
characteristics of mutations, as the E19del group has a
lower mutation burden and a higher ratio of transition
than the transversion mutations. Overall, the presence of
mutational signatures 5 and 30 was a predominant pat-
tern observed across the subtypes, but the main factors
related to this type of signature are still unknown, so
they require further in-depth studies on signature 5 and
30 in this particular subtype of lung cancer.
Conclusions
Lung adenocarcinoma with mEGFR(+) has a lower muta-
tional burden and does not show a characteristic mutation
pattern influenced by smoking. E19del and L858R, which
are representative subtypes of mEGFR(+) lung adenocar-
cinoma, differ in terms of mutational spectra, as the
E19del group has a lower mutation burden and a higher
Ti/Tv ratio. These findings could explain on the differ-
ences in the responses to EGFR-TKIs and clinical courses
between the two lung adenocarcinoma subgroups.
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